Dementia

This study is aimed at investigating the efficacy of a drug (JNJ-63733657) in delaying the progression of Alzheimer’s dementia by reducing the propagation of tau proteins. Participants will first attend a screen visit at the Royal Melbourne Hospital to ensure that they meet the criteria for the study. Once enrolled, they will be randomised in a 2:1 ratio to receive the drug or placebo.

Study duration is 4.5 years and will involve 36-38 visits to the Royal Melbourne Hospital throughout this time. Participants will receive the drug by way of intravenous infusion every 4 weeks.

Anticipated date that enrolment will close: December 2023

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Infectious Diseases

This is a clinical trial seeking to develop an mRNA vaccine for preventing Cytomegalovirus(CMV) infection. CMV infection is a common infection that can spread through saliva, blood, urine and breast milk. An infected healthy carrier normally has no symptoms, but symptoms may develop and include fever, muscles aches, moderate to severe fatigue, sore throat/swelling at back of throat, and/or swollen neck glands.

Infected pregnant women can infect their unborn child, causing congenital CMV infection. Infants with congenital CMV infection can have severe lifelong disabilities such as hearing loss, learning problems, vision abnormalities and potentially may be life-threatening, leading to death.

Anticipated date that enrolment will close: December 2022

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Psoriasis is a skin condition characterised by patches of skin that are typically red, itchy and scaly.

This study aims to understand the underlying mechanisms that trigger psoriasis and involves a one off-visit to clinics. The outcome of this project and knowledge gained will potentially support the development of new treatments for psoriasis and psoriatic arthritis.

Anticipated date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Prurigo nodularis (PN) is a chronic skin disease that characterised by hard, intensely itchy (puritus) lumps that form on the skin. Currently there are no approved therapies to treat PN.

KPL-716 is a drug made up of a protein known as an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody KPL-716 works by inhibiting certain inflammatory mediators and pathways involved in inflammation and pruritus.

The aim of the Kiniksa study is to assess the safety, efficacy and tolerability of the new drug in reducing pruritus in people with PN.

Anticipated date that enrolment will close: July 2022

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Basal cell carcinomas (BCC’s) are the most common skin cancer effecting Australians. Traditional first line treatment for BCC’s involves surgical excision but this can be quite invasive and suboptimal for certain tumours and patients, particularly when multiple tumours are present.

ASN-002 is a medication which contains interferon. Interferons Interferons are a group of signaling proteins made and released by host cells in response to the presence of several viruses. Intra-tumoural injections of interferons have been shown to be an effective treatment for non-melanoma skin cancers.

The aim of the Ascend study is to assess the safety and efficacy of ASN-002 combined with a hedgehog pathway inhibitor (Vismodegib) in the treatment of multiple low risk basal cell carcinomas in sporadic or basal cell naevus syndrome patients.

Anticipate date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Bullous pemphigoid (BP) is a rare, autoimmune skin condition characterised by blistering and itch. Many patients who have BP require treatment with topical steroids whilst others may require tablets, injections or infusions.

The investigational drug for this study is called benralizumab and given as an injection into the skin.

The purpose of this research project is to measure how safe and effective this medication is in treating participants with BP. Prior research studies in humans have shown that this medication may help regulate the immune system that is responsible for the signs and symptoms of BP and help achieve disease improvement.

Anticipated date that enrolment will close: Ongoing

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, commonly referred to as eczema, is a condition that makes your skin red, itchy and prone to infections. It can be treated with special creams for the skin, tablets or injections.

The investigational drug for this study is called Amlitelimab (KY1005) and given as an injection into the skin.

The purpose of this research project is to measure how safe and effective this medication is in treating participants with atopic dermatitis. Prior research studies in humans have shown that this medication may help control the immune system that is responsible for the signs and symptoms of atopic dermatitis and help achieve disease improvement.

Anticipate date that enrolment will close: January 2023

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Chronic spontaneous urticaria is a condition that is characterised by the appearance of weals (hives) and angioedema (swelling in the skin) that occur without a clear trigger. The drug we are studying for this project is called remibrutinib and will be provided to participants in the form of an oral tablet.

The purpose of this project is to measure how safe and effective this medication is in treating participants with chronic spontaneous urticaria.

Anticipated date that enrolment will close: January 2023

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4